- Home
- MBX vs ORIC Comparison
MBX vs ORIC Comparison
Compare MBX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBX
- ORIC
- Stock Information
- Founded
- MBX 36
- ORIC 2014
- Country
- MBX United States
- ORIC United States
- Employees
- MBX N/A
- ORIC N/A
- Industry
- MBX
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- MBX
- ORIC Health Care
- Exchange
- MBX NYSE
- ORIC Nasdaq
- Market Cap
- MBX 762.6M
- ORIC 633.7M
- IPO Year
- MBX 2024
- ORIC 2020
- Fundamental
- Price
- MBX $18.50
- ORIC $9.59
- Analyst Decision
- MBX Strong Buy
- ORIC Strong Buy
- Analyst Count
- MBX 4
- ORIC 9
- Target Price
- MBX $37.25
- ORIC $18.75
- AVG Volume (30 Days)
- MBX 96.8K
- ORIC 498.9K
- Earning Date
- MBX 11-07-2024
- ORIC 11-12-2024
- Dividend Yield
- MBX N/A
- ORIC N/A
- EPS Growth
- MBX N/A
- ORIC N/A
- EPS
- MBX N/A
- ORIC N/A
- Revenue
- MBX N/A
- ORIC N/A
- Revenue This Year
- MBX N/A
- ORIC N/A
- Revenue Next Year
- MBX N/A
- ORIC N/A
- P/E Ratio
- MBX N/A
- ORIC N/A
- Revenue Growth
- MBX N/A
- ORIC N/A
- 52 Week Low
- MBX $15.31
- ORIC $6.33
- 52 Week High
- MBX $27.50
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- MBX N/A
- ORIC 52.76
- Support Level
- MBX N/A
- ORIC $8.11
- Resistance Level
- MBX N/A
- ORIC $8.90
- Average True Range (ATR)
- MBX 0.00
- ORIC 0.74
- MACD
- MBX 0.00
- ORIC -0.04
- Stochastic Oscillator
- MBX 0.00
- ORIC 49.42
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.